Thermo Fisher Scientific (TMO), a leader in the medical device segment, is touted as an excellent investment choice in these turbulent times. Forecasts indicate a dip in Q1 earnings, but prospects remain positive as the firm continues to innovate in creating solutions to expedite the development of biologic therapeutics. Selling stock among insiders is raising some concerns, yet credible financial experts anticipate
massive upside potential and a robust 2025 fiscal performance. However,
increased tariffs and research funding reductions have compelled TMO to revise its 2025 profit forecast. They recently opened an advanced therapies center in San Diego and introduced various innovative technologies such as the 5L DynaDrive Single-Use Bioreactor which will accelerate process development. Wallstreet analysts are setting their sights on TMO shares with anticipation of a rebound. Notwithstanding, the Q1 performance did beat estimates, with TMO also completing a hefty
$3 billion buyback, implying a tangible conviction in their future trajectory.
Thermo Fisher Scientific TMO News Analytics from Fri, 15 Nov 2024 08:00:00 GMT to Sat, 10 May 2025 12:52:24 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -2
